PriceTargets.com logo

Establishment Labs - ESTA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $55.00
  • Forecasted Upside: 10.69%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$49.69 As of 04/23/2024 01:00 AM ET
▲ +1.42 (2.94%)

This chart shows the closing price for ESTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Establishment Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ESTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESTA

Analyst Price Target is $55.00
▲ +10.69% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Establishment Labs in the last 3 months. The average price target is $55.00, with a high forecast of $65.00 and a low forecast of $47.00. The average price target represents a 10.69% upside from the last price of $49.69.

This chart shows the closing price for ESTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Establishment Labs. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2024CitigroupBoost TargetBuy ➝ Buy$49.00 ➝ $60.00Low
4/1/2024MizuhoBoost TargetBuy ➝ Buy$50.00 ➝ $65.00Low
2/29/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$46.00 ➝ $53.00Low
1/11/2024StephensReiterated RatingOverweight ➝ Overweight$47.00Low
11/9/2023B. RileyLower TargetBuy ➝ Buy$95.00 ➝ $50.00Low
11/8/2023MizuhoLower TargetBuy ➝ Buy$80.00 ➝ $50.00Low
8/31/2023JPMorgan Chase & Co.Initiated CoverageOverweight$75.00Low
7/21/2023StephensReiterated RatingOverweight ➝ Overweight$89.00Low
6/29/2023CitigroupInitiated CoverageBuy$79.00Low
4/21/2023StephensReiterated RatingOverweight$89.00Low
4/21/2023MizuhoBoost TargetBuy$95.00 ➝ $110.00Low
4/17/2023BTIG ResearchBoost TargetBuy$100.00 ➝ $105.00Low
2/28/2023StephensBoost TargetOverweight$87.00 ➝ $89.00Low
1/24/2023MizuhoBoost TargetBuy$70.00 ➝ $95.00Low
12/28/2022StephensLower TargetOverweight$90.00 ➝ $87.00Low
10/13/2022StephensReiterated RatingOverweight$90.00Low
10/12/2022MizuhoInitiated CoverageBuy$70.00Low
10/7/2022BTIG ResearchBoost TargetBuy$90.00 ➝ $100.00Low
8/23/2022B. RileyInitiated CoverageBuy$107.00Low
8/9/2022The Goldman Sachs GroupBoost TargetNeutral$57.00 ➝ $65.00N/A
6/24/2022BTIG ResearchLower TargetBuy$105.00 ➝ $90.00Low
4/22/2022CowenBoost Target$95.00 ➝ $125.00High
4/22/2022CowenBoost Target$95.00 ➝ $125.00High
4/22/2022BTIG ResearchBoost TargetBuy$95.00 ➝ $110.00High
3/21/2022The Goldman Sachs GroupLower TargetNeutral$78.00 ➝ $67.00Medium
11/10/2021StephensBoost TargetOverweight$88.00 ➝ $90.00High
8/23/2021BTIG ResearchReiterated RatingBuyC$90.00High
8/3/2021The Goldman Sachs GroupBoost TargetNeutral$68.00 ➝ $78.00N/A
7/30/2021Jefferies Financial GroupInitiated CoverageBuy$90.00Low
6/23/2021BTIG ResearchBoost TargetBuy$82.00 ➝ $88.00Medium
2/10/2021CowenBoost TargetOutperform$60.00 ➝ $80.00Low
1/13/2021BTIG ResearchBoost TargetBuy$41.00 ➝ $61.00High
9/21/2020BTIG ResearchReiterated RatingBuyHigh
8/27/2020UBS GroupInitiated CoverageBuy$23.00Medium
8/7/2020BTIG ResearchReiterated RatingBuy$33.00High
5/14/2020The Goldman Sachs GroupInitiated CoverageNeutral$20.00Medium
5/7/2020BTIG ResearchReiterated RatingBuy$35.00Medium
3/23/2020StephensLower TargetOverweight$30.00 ➝ $23.00Low
3/17/2020BTIG ResearchLower TargetBuy$40.00 ➝ $35.00High
2/5/2020BTIG ResearchInitiated CoverageBuy$40.00Low
7/12/2019Wells Fargo & CompanySet TargetBuy$29.00Low
6/28/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$29.00High
6/6/2019StephensInitiated CoverageOverweight$37.00Medium
5/16/2019BTIG ResearchReiterated RatingBuy$40.00Low
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 7 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 7 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 7 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Establishment Labs logo
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Read More

Today's Range

Now: $49.69
Low: $47.92
High: $50.03

50 Day Range

MA: $47.55
Low: $35.80
High: $55.38

52 Week Range

Now: $49.69
Low: $16.96
High: $75.24

Volume

266,011 shs

Average Volume

327,869 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Establishment Labs?

The following sell-side analysts have issued research reports on Establishment Labs in the last year: B. Riley, Citigroup Inc., JPMorgan Chase & Co., Mizuho, and Stephens.
View the latest analyst ratings for ESTA.

What is the current price target for Establishment Labs?

5 Wall Street analysts have set twelve-month price targets for Establishment Labs in the last year. Their average twelve-month price target is $55.00, suggesting a possible upside of 10.7%. Mizuho has the highest price target set, predicting ESTA will reach $65.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $47.00 for Establishment Labs in the next year.
View the latest price targets for ESTA.

What is the current consensus analyst rating for Establishment Labs?

Establishment Labs currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ESTA will outperform the market and that investors should add to their positions of Establishment Labs.
View the latest ratings for ESTA.

What other companies compete with Establishment Labs?

Other companies that are similar to Establishment Labs include Eargo, Avanos Medical, Jin Medical International, Inogen and Invacare. Learn More about companies similar to Establishment Labs.

How do I contact Establishment Labs' investor relations team?

Establishment Labs' physical mailing address is Building B15 and 25 Coyol Free Zone, Alajuela G2, . The company's listed phone number is (062) 434-2400 and its investor relations email address is [email protected]. The official website for Establishment Labs is www.establishmentlabs.com. Learn More about contacing Establishment Labs investor relations.